試題詳解

76. 關於 HCC systemic therapy 的敘述下列何者正確？
(1) Systemic chemotherapy with doxorubicin or FOLFOX did not demonstrate
survival benefits
(2) Lenvatinib targets VEGFR1-3; fibroblast growth factor receptor (FGFR1-4);
platelet-derived growth factor receptor α, RET, and KIT
(3) Cabozantinib is a MET, VEGFR2 and RET inhibitor approved for thyroid,
renal cancer and HCC
(4) Ramucirumab is a monoclonal antibody targeting VEGFR 2
(5) Atezolizumab plus cabozantinib showed a superiority to sorafenib in median progression-free survival (PFS)
(A) (1)＋(2)
(B) (1)＋(2)＋(3)
(C) (2)＋(3)＋(4)
(D) (1)＋(2)＋(3)＋(5)

(E) (1)＋(2)＋(3)＋(4)＋(5)